Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. (linkinghub.elsevier.com)

Authors: Mora P … Rosenstock J Journal: The Lancet Published: 2026-07-30 DOI: https://doi.org/10.1016/S0140-6736(26)01248-1